🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This phase Ib trial is to find out the best dose, possible benefits and/or ...
Status
Recruiting
Location
M D Anderson Cancer Center
Start Date
2020-12-01
Trial ID
NCT04693468
Treatments Being Tested
Avelumab in combination with talazoparib will be investigated in patients w...
Status
Terminated
Location
Highlands Oncology Group
Start Date
2017-10-19
Trial ID
NCT03330405
Treatments Being Tested
This phase I/Ib trial studies the side effects and best dose of talazoparib...
Status
Completed
Location
University of Maryland Greenebaum Cancer Center
Start Date
2020-10-23
Trial ID
NCT04207190
This Phase 1b/2 study will examine the effects of the study drugs, avelumab...
Status
Terminated
Location
Highlands Oncology Group
Start Date
2018-08-15
Trial ID
NCT03637491
Treatments Being Tested
This research is studying the effect of Antibody-Drug Conjugate Sacituzumab...
Status
Active Not Recruiting
Location
Massachusetts General Hospital Cancer Center
Start Date
2019-10-09
Trial ID
NCT04039230
Treatments Being Tested
The purpose of this phase 2, multiple-cohort, randomized, open-label, inter...
Status
Withdrawn
Location
Multiple Locations
Start Date
2016-10
Trial ID
NCT02836028
Treatments Being Tested
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) i...
Status
Terminated
Location
University of Rochester Medical Center
Start Date
2019-12-30
Trial ID
NCT04052204
Treatments Being Tested
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D)...
Status
Terminated
Location
University of Alabama
Start Date
2019-05-20
Trial ID
NCT03875313
Treatments Being Tested
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TN...
Status
Terminated
Location
University of Alabama at Birmingham
Start Date
2021-08-24
Trial ID
NCT04849364
Treatments Being Tested